Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...

(Atossa Therapeutics Investors) We are vigorously defending Atossa's intellectual property, which is subject of the ongoing U.S. Patent and Trademark Office (USPTO) proceedings with Intas ...

For life to survive, it needs to respond to challenges, particularly by adapting the activity of its immune system. As we have seen with Covid, outside infectious agents are constantly trying to gain ...

Atossa Therapeutics, Inc. announced the granting of a new patent (U.S. Patent No. 12,275,684) by the USPTO for its enteric oral formulations of (Z)-endoxifen, a potent Selective Estrogen Receptor ...

SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive ...